Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Canada / NCT05709132
Recruiting Not applicable

iP2P Mentorship Program for Adolescent HF Patients

NCT05709132 · tracked via the Priya Life Science Canada tracker
Sponsor
The Hospital for Sick Children
Phase
Not applicable
Started
2024-01-01
Last updated
2025-07-09

Condition(s) studied

Heart Failure

Investigational drug(s) / intervention(s)

iPeer2Peer Program

iPeer2Peer Program: Behavioral: iPeer2Peer Support Mentorship Program is an online peer support mentorship program that has been established in multiple chronic disease populations as a self-management intervention, including chronic pain and juvenile idiopathic arthritis. The iPeer2Peer program provides modeling and reinforcement by pre-screened and trained young adult peer mentors to adolescent mentees.

Study summary

The iPeer2Peer (iP2P) program is an online peer support mentorship program that provides modelling and reinforcement by trained young adult peer mentors to adolescent mentees with the same condition. A quasi-experimental single-arm pre-post study design will be employed across three sites. We will recruit 40 mentees (12-17 years of age) and 12-15 mentors (18-30 years of age) who will undergo training in mentoring and the use of eHealth technology. Mentor-mentee pairings will connect over 15 weeks through video calls and text messaging to provide peer support and encourage disease self-management skills. Data will be collected using standardized instruments and interviews across three time points.

Eligibility

Sex
ALL
Min age
12 Years
Max age
30 Years
Healthy volunteers
No
Mentee inclusion criteria: 1. patient with a cardiac diagnosis, 2. at least 4 months post-diagnosis, 3. between the ages of 12 and 17 years, 4. able to speak and read English, and 5. willingness to commit to 5-10 texts and/or calls of 20-30 minutes each with a peer mentor over a period of 15 weeks. Mentor inclusion criteria: 1. patient with a cardiac diagnosis, 2. between the ages of 18 and 30 years, 3. able to speak and read English, 4. nominated by a member of their health care team as a good mentor based on maturity and emotional stability, 5. willingness to commit to peer mentor training (20 hours) via the PHIPA-compliant version of Zoom or Microsoft Teams and mentoring adolescent participants (once paired with mentee, 5-10 texts and/or calls of 20-30 minutes over a period of 15 weeks), 6. good communication skills (as assessed by a healthcare provider), and 7. previous experience in a professional environment (e.g., as a camp counsellor, part time job, volunteering) is an asset. Exclusion Criteria: 1. significant cognitive impairments as assessed by a qualified healthcare provider, 2. a diagnosis of an active psychological disorder (e.g., Major Depressive Disorder, Generalized Anxiety Disorder) likely to influence assessment of health-related quality of life and/or interfere with their ability to manage their heart failure care regimen (a diagnosis of an active psychological disorder will be determined for mentees through medical chart review and self-reported by mentors), and 3. participating in other peer support or self-management interventions.

Primary outcome measure(s)

  • Acceptability (Mentees) — 15 weeks after baseline/immediately after the intervention
    Whether the innovation is agreeable, palatable or satisfactory
  • Acceptability (Mentors) — Study completion, an average of 1 year
    Whether the innovation is agreeable, palatable or satisfactory
  • Adoption (Mentees) — Baseline to 12 weeks post-program completion
    The intention, initial decision or action to try or use an innovation
  • Adoption (Mentors) — Baseline to study completion, an average of 1 year
    The intention, initial decision or action to try or use an innovation
  • Feasibility (Mentees) — Baseline to 12 weeks post-program completion
    The extent to which an innovation can be used or carried out successfully in a given setting
  • Feasibility (Mentors) — Baseline to study completion, an average of 1 year
    The extent to which an innovation can be used or carried out successfully in a given setting
  • Appropriateness (Mentees) — Baseline to 12 weeks post-program completion
    The perceived fit, relevance or compatibility of the innovation for a practice setting; and/or its perceived fit to address an issue or problem
  • Appropriateness (Mentors) — Baseline to study completion, an average of 1 year
    The perceived fit, relevance or compatibility of the innovation for a practice setting; and/or its perceived fit to address an issue or problem
  • Level of engagement (Mentees) — 15 weeks after baseline/immediately after the intervention
  • Level of engagement (Mentors) — Study completion, an average of 1 year

Trial sites (1)

FacilityCityRegionStatus
The Hospital for Sick Children Toronto Ontario Recruiting

More The Hospital for Sick Children trials in Canada

Effort of Breathing and Dyssynchrony Burden During Assisted Ventilation in Paediatric Patients Starting soon
Vomiting Prevention in Children With Cancer Active, not recruiting
Xenon-129 and Inert Fluorinated Gas Lung MRI: Study of Healthy Volunteers and Participants With Pulmonary Disease Recruiting
ATOMIC (Active Teens Multiple Sclerosis) Physical Activity Research Program Active, not recruiting
UCAN CAN-DU: Canada-Netherlands Personalized Medicine Network in Childhood Arthritis and Rheumatic Disease Recruiting

Other trials for the same condition

A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart Recruiting
WeRoaM: Wearable Remote Monitoring in Heart Failure Recruiting
Screening for earlY Heart Failure Diagnosis and Management in Primary Care or at HOme Using Natriuretic Peptides and echocardiographY "SYMPHONY-HF" Recruiting
LEFT ATRIAL MONITORING IN PATIENTS BEFORE AND AFTER MITRAL SURGERY - LAMBDA STUDY Recruiting
RESPONDER-HF Trial Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05709132 on ClinicalTrials.gov ↗ ← All trials in Canada